Medical - Equipment & Services
Compare Stocks
4 / 10Stock Comparison
CON vs DBVT vs ALKS vs AMSF
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Insurance - Specialty
CON vs DBVT vs ALKS vs AMSF — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Equipment & Services | Biotechnology | Biotechnology | Insurance - Specialty |
| Market Cap | $3.03B | $1712.35T | $5.90B | $569M |
| Revenue (TTM) | $2.23B | $0.00 | $1.56B | $325M |
| Net Income (TTM) | $178M | $-168M | $153M | $46M |
| Gross Margin | 28.7% | — | 65.4% | 47.6% |
| Operating Margin | 89.9% | — | 12.3% | 17.8% |
| Forward P/E | 16.2x | — | 24.8x | 14.4x |
| Total Debt | $2.10B | $22M | $70M | $491K |
| Cash & Equiv. | $80M | $194M | $1.12B | $62M |
CON vs DBVT vs ALKS vs AMSF — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Concentra Group Hol… (CON) | 100 | 101.3 | +1.3% |
| DBV Technologies S.… (DBVT) | 100 | 330.4 | +230.4% |
| Alkermes plc (ALKS) | 100 | 129.6 | +29.6% |
| AMERISAFE, Inc. (AMSF) | 100 | 63.8 | -36.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CON vs DBVT vs ALKS vs AMSF
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CON is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 13.9%, EPS growth 0.0%, 3Y rev CAGR 7.9%
- 13.9% revenue growth vs DBVT's -100.0%
- 6.1% ROA vs DBVT's -89.0%
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs AMSF's -29.2%
ALKS lags the leaders in this set but could rank higher in a more targeted comparison.
AMSF carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 0.23, yield 8.4%
- 31.8% 10Y total return vs CON's 6.7%
- Lower volatility, beta 0.23, Low D/E 0.2%, current ratio 0.32x
- Beta 0.23, yield 8.4%, current ratio 0.32x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.9% revenue growth vs DBVT's -100.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 14.3% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.23 vs DBVT's 1.26, lower leverage | |
| Dividends | 8.4% yield, vs CON's 1.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs AMSF's -29.2% | |
| Efficiency (ROA) | 6.1% ROA vs DBVT's -89.0% |
CON vs DBVT vs ALKS vs AMSF — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
CON vs DBVT vs ALKS vs AMSF — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 1 of 6 categories
CON leads 1 • DBVT leads 1 • AMSF leads 1 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CON and DBVT operate at a comparable scale, with $2.2B and $0 in trailing revenue. AMSF is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to CON's 8.0%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $2.2B | $0 | $1.6B | $325M |
| EBITDAEarnings before interest/tax | $2.1B | -$112M | $212M | $58M |
| Net IncomeAfter-tax profit | $178M | -$168M | $153M | $46M |
| Free Cash FlowCash after capex | $293M | -$151M | $392M | $8M |
| Gross MarginGross profit ÷ Revenue | +28.7% | — | +65.4% | +47.6% |
| Operating MarginEBIT ÷ Revenue | +89.9% | — | +12.3% | +17.8% |
| Net MarginNet income ÷ Revenue | +8.0% | — | +9.8% | +14.3% |
| FCF MarginFCF ÷ Revenue | +13.1% | — | +25.1% | +2.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.7% | — | +28.2% | +10.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.8% | +91.5% | -4.1% | -8.5% |
Valuation Metrics
Evenly matched — CON and DBVT each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 12.3x trailing earnings, AMSF trades at a 50% valuation discount to ALKS's 24.8x P/E. On an enterprise value basis, CON's 2.3x EV/EBITDA is more attractive than ALKS's 17.3x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3.0B | $1712.35T | $5.9B | $569M |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $1712.35T | $4.9B | $508M |
| Trailing P/EPrice ÷ TTM EPS | 18.16x | -0.76x | 24.76x | 12.27x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.18x | — | — | 14.42x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 2.34x | — | 17.25x | 8.53x |
| Price / SalesMarket cap ÷ Revenue | 1.40x | — | 4.00x | 1.80x |
| Price / BookPrice ÷ Book value/share | 7.20x | 0.66x | 3.28x | 2.30x |
| Price / FCFMarket cap ÷ FCF | 15.40x | — | 12.28x | 63.83x |
Profitability & Efficiency
CON leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
CON delivers a 43.7% return on equity — every $100 of shareholder capital generates $44 in annual profit, vs $-130 for DBVT. AMSF carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CON's 5.00x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +43.7% | -130.2% | +8.8% | +9.7% |
| ROA (TTM)Return on assets | +6.1% | -89.0% | +5.4% | +5.6% |
| ROICReturn on invested capital | +69.4% | — | +18.9% | +21.9% |
| ROCEReturn on capital employed | +84.9% | -145.7% | +14.2% | +16.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 7 | 7 |
| Debt / EquityFinancial leverage | 5.00x | 0.13x | 0.04x | 0.00x |
| Net DebtTotal debt minus cash | $2.0B | -$172M | -$1.0B | -$61M |
| Cash & Equiv.Liquid assets | $80M | $194M | $1.1B | $62M |
| Total DebtShort + long-term debt | $2.1B | $22M | $70M | $491,000 |
| Interest CoverageEBIT ÷ Interest expense | 4.59x | -189.82x | 32.30x | — |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs AMSF's -29.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs AMSF's -9.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.0% | +4.9% | +25.3% | -18.3% |
| 1-Year ReturnPast 12 months | +9.1% | +110.4% | +16.5% | -29.2% |
| 3-Year ReturnCumulative with dividends | +6.7% | +19.7% | +14.5% | -24.8% |
| 5-Year ReturnCumulative with dividends | +6.7% | -69.1% | +60.9% | -18.9% |
| 10-Year ReturnCumulative with dividends | +6.7% | -87.0% | -11.0% | +31.8% |
| CAGR (3Y)Annualised 3-year return | +2.2% | +6.2% | +4.6% | -9.1% |
Risk & Volatility
Evenly matched — ALKS and AMSF each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMSF is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs AMSF's 62.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.69x | 1.26x | 1.06x | 0.23x |
| 52-Week HighHighest price in past year | $24.68 | $26.18 | $36.60 | $48.54 |
| 52-Week LowLowest price in past year | $18.55 | $7.53 | $25.17 | $29.42 |
| % of 52W HighCurrent price vs 52-week peak | +95.6% | +76.3% | +96.7% | +62.4% |
| RSI (14)Momentum oscillator 0–100 | 56.1 | 48.1 | 60.2 | 34.2 |
| Avg Volume (50D)Average daily shares traded | 654K | 252K | 2.3M | 212K |
Analyst Outlook
AMSF leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CON as "Buy", DBVT as "Buy", ALKS as "Buy", AMSF as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44). For income investors, AMSF offers the higher dividend yield at 8.41% vs CON's 1.06%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $31.00 | $46.33 | $44.00 | $44.50 |
| # AnalystsCovering analysts | 4 | 15 | 28 | 6 |
| Dividend YieldAnnual dividend ÷ price | +1.1% | — | — | +8.4% |
| Dividend StreakConsecutive years of raises | 0 | 0 | 0 | 0 |
| Dividend / ShareAnnual DPS | $0.25 | — | — | $2.55 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% | +0.5% | +2.1% |
ALKS leads in 1 of 6 categories (Income & Cash Flow). CON leads in 1 (Profitability & Efficiency). 2 tied.
CON vs DBVT vs ALKS vs AMSF: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CON or DBVT or ALKS or AMSF a better buy right now?
For growth investors, Concentra Group Holdings Parent, Inc.
(CON) is the stronger pick with 13. 9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). AMERISAFE, Inc. (AMSF) offers the better valuation at 12. 3x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Concentra Group Holdings Parent, Inc. (CON) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CON or DBVT or ALKS or AMSF?
On trailing P/E, AMERISAFE, Inc.
(AMSF) is the cheapest at 12. 3x versus Alkermes plc at 24. 8x. On forward P/E, AMERISAFE, Inc. is actually cheaper at 14. 4x.
03Which is the better long-term investment — CON or DBVT or ALKS or AMSF?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: AMSF returned +31. 8% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CON or DBVT or ALKS or AMSF?
By beta (market sensitivity over 5 years), AMERISAFE, Inc.
(AMSF) is the lower-risk stock at 0. 23β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 444% more volatile than AMSF relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 5% for Concentra Group Holdings Parent, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CON or DBVT or ALKS or AMSF?
By revenue growth (latest reported year), Concentra Group Holdings Parent, Inc.
(CON) is pulling ahead at 13. 9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Concentra Group Holdings Parent, Inc. grew EPS 0. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CON or DBVT or ALKS or AMSF?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CON leads at 96. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CON or DBVT or ALKS or AMSF more undervalued right now?
On forward earnings alone, AMERISAFE, Inc.
(AMSF) trades at 14. 4x forward P/E versus 16. 2x for Concentra Group Holdings Parent, Inc. — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — CON or DBVT or ALKS or AMSF?
In this comparison, AMSF (8.
4% yield), CON (1. 1% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is CON or DBVT or ALKS or AMSF better for a retirement portfolio?
For long-horizon retirement investors, AMERISAFE, Inc.
(AMSF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), 8. 4% yield). Both have compounded well over 10 years (AMSF: +31. 8%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CON and DBVT and ALKS and AMSF?
These companies operate in different sectors (CON (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and AMSF (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CON is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; AMSF is a small-cap deep-value stock. CON, AMSF pay a dividend while DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.